Pfizer exec says China's biotech growth will decelerate as firms hit R&D frontier

Andrew Baum of Pfizer told Endpoints News that China's rapid biotech progress is expected to slow as companies move into more advanced research and development.

He explained that as Chinese firms begin to tackle cutting‑edge biology, the inherent scientific and regulatory risks increase, which could temper the pace of new developments.

Baum suggested that this shift may lead to a more cautious investment environment and could affect the overall momentum of China's biotech sector.